Sugi Predict

Sugi Predict / Compounds / SCHEMBL18921008

SCHEMBL18921008

SCHEMBL18921008

CC(C)(C)OC(=O)CCC(N)C(=O)Nc1ccc(CO)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SPHK1 Q9NYA1 7/20 0.47
▸ SPHK2 Q9NRA0 1/20 0.47
▸ LTA4H P09960 5/20 0.46
▸ S1PR1 P21453 6/20 0.44
▸ S1PR3 Q99500 6/20 0.44
▸ S1PR4 O95977 4/20 0.41
▸ S1PR5 Q9H228 4/20 0.41
▸ S1PR2 O95136 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.39
▸ ADCY6 O43306 1/20 0.39
▸ ADCY3 O60266 1/20 0.39
▸ ADCY9 O60503 1/20 0.39
▸ ADCY5 O95622 1/20 0.39
▸ ADCY8 P40145 1/20 0.39
▸ GCGR P47871 1/20 0.39
▸ ADCY7 P51828 1/20 0.39
▸ ADCY2 Q08462 1/20 0.39
▸ ADCY1 Q08828 1/20 0.39
▸ ADCY4 Q8NFM4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18921010 1.00 SPHK1 (0.47) SPHK1SPHK2LTA4HS1PR1S1PR3
SCHEMBL29307826 0.90 SPHK1 (0.47) SPHK1SPHK2LTA4HS1PR1S1PR3
SCHEMBL2670047 0.87 SPHK1 (0.45) SPHK1SPHK2LTA4HS1PR1S1PR3
SCHEMBL2670045 0.87 SPHK1 (0.45) SPHK1SPHK2LTA4HS1PR1S1PR3
SCHEMBL6290636 0.86 S1PR1 (0.45) SPHK1SPHK2LTA4HS1PR1S1PR3
SCHEMBL29308003 0.86 HSD17B10 (0.42) LTA4HHDAC8ADCY6ADCY3ADCY9
SCHEMBL23132270 0.81 SPHK1 (0.46) SPHK1SPHK2LTA4HS1PR1S1PR3
SCHEMBL20067638 0.80 SPHK1 (0.49) SPHK1SPHK2LTA4H
SCHEMBL22457856 0.80 SUV39H2 (0.46) SPHK1SPHK2S1PR1S1PR3S1PR4
SCHEMBL23125175 0.80 LTA4H (0.62) SPHK1SPHK2LTA4HS1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240247030-A1 TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES JPMORGAN CHASE BANK, N.A. 2024-07-25 — — US disclosed
US-20240156969-A1 CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS SEAGEN INC (US) 2024-05-16 — — US disclosed
EP-3900742-B1 TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES SEAGEN INC (US) 2024-05-15 — — EP disclosed
CN-114732916-B Targeted delivery of tertiary amine-containing drug substances 西雅图基因公司 2023-12-19 — — CN disclosed
CN-117120097-A Selective drug release of internalized bioactive compound conjugates 思进公司 2023-11-24 — — CN disclosed
CN-117120098-A Selective drug release of internalized bioactive compound conjugates 思进公司 2023-11-24 — — CN disclosed
US-11793880-B2 Conjugates of quaternized tubulysin compounds SEAGEN INC. (US) 2023-10-24 — — US disclosed
EP-4074328-A1 INTERMEDIATES OF CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS Seagen Inc. (US) 2022-10-19 — — EP disclosed
US-20220226482-A1 CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS SEAGEN INC (US) 2022-07-21 — — US disclosed
CN-114732916-A Targeted delivery of tertiary amine-containing drug substances 西雅图基因公司 2022-07-12 — — CN disclosed
CN-107108694-B Targeted delivery of tertiary amine-containing drug substances 西雅图基因公司 2022-05-03 — — CN disclosed
EP-3383420-B1 CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS SEAGEN INC (US) 2022-03-23 — — EP disclosed
US-11229708-B2 Conjugates of quaternized tubulysin compounds SEAGEN INC. (US) 2022-01-25 — — US disclosed
CN-113827737-A Targeted delivery of tertiary amine-containing drug substances 西雅图基因公司 2021-12-24 — — CN disclosed
EP-3900742-A1 TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES Seagen Inc. (US) 2021-10-27 — — EP disclosed
EP-3191502-B1 TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES SEAGEN INC (US) 2021-04-21 — — EP disclosed
US-20190015517-A1 CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS SEATTLE GENETICS, INC. (US) 2019-01-17 — — US disclosed
EP-3383420-A1 CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS Seattle Genetics, Inc. (US) 2018-10-10 — — EP disclosed
US-20170247412-A1 TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES SEATTLE GENETICS, INC. (US) 2017-08-31 — — US disclosed
WO-2017096311-A1 CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS SEATTLE GENETICS, INC. (US) 2017-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170247412-A1 TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES CD47, CD44, MSR1 SPHK1 1831/4885SPHK2 1564/4885LTA4H 2192/4885
US-20240247030-A1 TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES CD47, CD44, MSR1 SPHK1 1831/4885SPHK2 1564/4885LTA4H 2192/4885
US-20220226482-A1 CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS LCK, UACA, TEKT1 SPHK1 2956/4885SPHK2 2807/4885LTA4H 2924/4885
US-11229708-B2 Conjugates of quaternized tubulysin compounds LCK, UACA, TEKT1 SPHK1 2956/4885SPHK2 2807/4885LTA4H 2924/4885
US-20190015517-A1 CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS LCK, UACA, TEKT1 SPHK1 2956/4885SPHK2 2807/4885LTA4H 2924/4885
US-20240156969-A1 CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS LCK, UACA, TEKT1 SPHK1 2956/4885SPHK2 2807/4885LTA4H 2924/4885
US-11793880-B2 Conjugates of quaternized tubulysin compounds LCK, UACA, TEKT1 SPHK1 2956/4885SPHK2 2807/4885LTA4H 2924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.